PB2102: PHASE 2 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLAMOTAMAB COMBINED WITH TAFASITAMAB (TAFA) + LENALIDOMIDE (LEN) VS TAFA+LEN IN RELAPSED OR REFRACTORY DLBCL

ABSTRACT:

SUBMITTER: Michot J 

PROVIDER: S-EPMC9431672 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature